CCND1 and primary effusion lymphoma: Granato et al. suggested that QUE inhibited the PI3K/AKT/mTOR and STAT3 pathways in primary effusion lymphoma (PEL), an aggressive B-cell lymphoma, reducing the expression of pro-survival cellular proteins such as c-FLIP, cyclin D1, and c-Myc, and the release of the cytokines IL-6 and IL-10, leading to PEL cell death [151].